News

Racial disparities in biomarkers highlight the need to investigate different populations in trials of Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 19, 2021.

Masahito Kawabori, MD, PhD, associate professor, Hokkaido University, discussed results of the phase 2 STEMTRA trial.

The founder and director of the Sleep Centers of Middle Tennessee discussed how patients that better understand the benefits of PAP therapy had better adherence to the therapy.

Surgical treatment for epilepsy has been proven its effectiveness, and preoperative evaluation has sparked a debate: to spare or not to spare the hippocampus?

Overall, variants within known ALS-linked genes are of potential clinical importance for 42% of patients, according to the study authors.

Investigators identified no additional benefit nor harm from the use of low-dose alteplase to treat patients with lacunar acute ischemic stroke compared to other subtypes of AIS.

Scholz was recognized for her application of advanced genetic techniques to the study of neurodegenerative disorders, including dementia with Lewy bodies, multiple system atrophy, frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration.

The director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic shared the next steps in building on previous research that links exercise with a reduced Alzheimer disease risk.

Jennifer Martin, PhD, AASM board of directors' member and professor of medicine at UCLA discussed CBI-T and some of the challenges in treating patients with chronic insomnia.

Researchers also found that patients treated with autologous hematopoietic stem cell transplantation had higher rates of infection then other DMT-treated groups.

The director of the Montefiore Headache Center discussed the impact of halving headache days for patients with migraine.

The duo from Vanderbilt University discussed the lack of awareness for functional seizures, their differences in treatment, and what needs to change about their current management.

Alector’s announcement about the INVOKE-2 study follows a similar update regarding its INFRONT-3 study for frontotemporal dementia.

A roundtable discussion featuring Scott Perry, MD, Orrin Devinsky, MD, and Tracy Salazar, PhD, details how advocacy organizations can help guide patients with epilepsy and their caregivers with a seizure action plan.

Patients who had a mobile stroke unit dispatched had lower 3-month coprimary disability score.

The DMD treatment pipeline boasts a number of therapeutics with varying mechanisms of action and delivery systems, pointing to a promising future for treatment.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed a recently initiated study that will look at the FDA-approved cancer drug lenalidomide for the treatment of Alzheimer disease.

The calcium, magnesium, potassium, and sodium oxybates solution, marketed as Xywav, was approved for cataplexy and daytime sleepiness in narcolepsy in July 2020.

The neurologist from Cleveland Clinic discussed how patients with early-onset NMOSD were more likely to have severe residual vision loss.

The Biomodex-developed models have also been studied in pre-procedural rehearsal for brain aneurysms.

A roundtable discussion featuring Scott Perry, MD, Orrin Devinsky, MD, and Tracy Salazar, PhD, details how seizure action plans change from pediatrics to adults and the need for adjustments.

ElectroCore announced that the expanded indication, noting that gammaCore is now the only acute and preventive option approved for both adult and adolescent migraine.

The assistant professor of neurology at Thomas Jefferson University provided perspective on how researchers have gained a better understanding of using modalities in poststroke patients.

Researchers observed statistically significant improvements of the EDSS score along with a majority of patients showing no new enlarging or gadolinium-enhancing MRI lesions.

Researchers found that 93% of patients with AS exhibited dystonia in their limbs, mouth, neck, or trunk.

With promising data presented at WORLDSymposium 2021 and a PDUFA date looming in May, investigator Priya S. Kishnani, MD, offered her insight on Sanofi’s investigational therapy.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine discussed observing how sleep may impact cognitive decline in different populations.

Using the largest existing cEEG data set, researchers identified seizure chronotypes at multiple timescales, noting that circadian and multidien seizure cycles are equally strong and highly prevalent.